Noom streamlines Zepbound access
Noom
This integration turns Noom from a coaching app that can also write prescriptions into a cleaner checkout lane for branded obesity drugs. The practical change is that an eligible member can move from Noom screening and prescribing into LillyDirect fulfillment through Gifthealth, then track fill status and shipping inside Noom, instead of bouncing between a telehealth visit, a separate pharmacy workflow, and text or email updates. That makes branded GLP-1 access feel like one product, not three disconnected services.
-
The timing matters because the market was shifting away from shortage era compounding and back toward manufacturer controlled supply. Lilly expanded Zepbound vial availability through LillyDirect in 2024 and 2025, giving telehealth platforms a compliant self pay path for authentic branded drug fulfillment.
-
Noom is following the same playbook as other telehealth companies including LifeMD, Nurx, Sesame, and WeightWatchers, all of which announced Gifthealth or LillyDirect links for Zepbound in 2025. The new competitive edge is less about writing the prescription, and more about making access, payment, and refill logistics frictionless.
-
This fits Noom’s broader position in weight loss. Noom built a large consumer business around food logging, behavior change lessons, and coaching, then added GLP-1 prescribing as obesity drugs became central to the category. The LillyDirect link lets Noom keep the behavior layer while plugging into branded drug distribution it does not need to own itself.
The next step is a tighter blend of manufacturer supply, telehealth prescribing, and longitudinal coaching. As branded GLP-1 access becomes easier to compare across apps, the winners in weight loss will look more like care orchestration layers, combining medication access, adherence support, and habit change in one interface that keeps members engaged for longer.